| Literature DB >> 27864806 |
Francesco Maranta1, Roberto Spoladore1, Gabriele Fragasso2.
Abstract
Treating arterial hypertension (HT) remains a hard task. The hypertensive patient is often a subject with several comorbidities and metabolic abnormalities. Clinicians everyday have to choose the right drug for the single patient among the different classes of antihypertensives. Apart from lowering blood pressure, a main therapeutic target should be that of counteracting all the possible pathophysiological mechanisms involved in HT itself and in existing/potential comorbidities. All the ancillary positive and negative effects of the administered drugs should be considered: in particular, since hypertensive patients are often glucose intolerant/diabetic, carrier of serum lipids disorder, have already developed atherosclerotic diseases and endothelial dysfunction, they should not be treated with drugs negatively interfering with these conditions but with molecules that, if possible, improve them. The main pathophysiological mechanisms and correlates of therapeutic pharmacological interventions in essential HT are reviewed here.Entities:
Keywords: ACE-inhibition; Beta-blockers; Hyperglycemia; Hypertension; Metabolic syndrome; Pathophysiology; RAAS inhibition; Side effects; Therapy; Thiazides diuretics
Mesh:
Substances:
Year: 2017 PMID: 27864806 DOI: 10.1007/5584_2016_169
Source DB: PubMed Journal: Adv Exp Med Biol ISSN: 0065-2598 Impact factor: 2.622